Entera Bio Ltd. (ENTX) News
Follow Entera Bio Ltd. (ENTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Entera Bio Reports $15.6 Million Q3 2026 Net Loss
Entera reported a $15.6 million net loss for Q3 2026, versus $3.2 million a year earlier. The loss included a $7.5 million non-cash warrant remeasurement. Cash and cash equivalents were $265.9 million at September 30; th
EQUITY | Nov 06, 2026, 09:16 PM UTC
M
Entera Reports Third-Quarter 2026 Results and Business Updates
Entera said preparations advanced for its EB613 Phase 3 osteoporosis study, with first site activation expected in late 2026. The company also expanded clinical and commercial leadership and highlighted EB613 at an ASBMR
EQUITY | Nov 06, 2026, 09:16 PM UTC
L
Weekly Recap: FDA OK for EB613 Phase 3 and $275M raise into 2030
Entera Bio Ltd. (NASDAQ:ENTX) secured FDA positive feedback on its EB613 Phase 3—~750 postmenopausal women with 12—month hip BMD primary endpoint and topline data due H2 2028—after an oversubscribed July 2026 $275M priva
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Entera Bio Price Target Announced at $11.00/Share by Guggenheim
Ratings actions from Benzinga: GMT) Entera Bio Initiated at Buy by GuggenheimRatings actions from Benzinga
NEWS | Sep 25, 2026, 01:07 PM UTC
L
Guggenheim initiates coverage of Entera Bio with Buy rating, $11 price target
Guggenheim initiated coverage on Entera Bio's stock with a rating of Buy and a price target of $11.00.The price target implies an upside of 292.9% from the Sep 24 close of $2.80.Key takeaways from the analyst noteInnovat
EQUITY | Sep 25, 2026, 01:03 PM UTC
L
Entera Bio initiated by Leerink with $9 target, Outperform rating
Leerink Partners initiated coverage on Entera Bio Ltd. (ENTX) with an ‘Outperform’ rating and a $9 price target. ENTX closed at $3.03 per share on September 17, 2026.
EQUITY | Sep 18, 2026, 12:21 PM UTC
L
ENTX - Correction: Entera to Participate in Upcoming Fall Investor Conferences
ENTX - Correction: Entera to Participate in Upcoming Fall Investor Conferences
EQUITY | Aug 27, 2026, 01:44 PM UTC
L
Entera to participate in upcoming fall investor conferences
Entera says it will participate in upcoming fall investor conferences.
EQUITY | Aug 27, 2026, 12:07 PM UTC
L
ENTX - Entera to Participate in Upcoming Fall Investor Conferences
ENTX - Entera to Participate in Upcoming Fall Investor Conferences
EQUITY | Aug 27, 2026, 12:02 PM UTC
M
ENTX files S-3 for 134,803,910 ordinary shares
ENTX files Form S-3 covering 134,803,910 ordinary shares offered by the selling shareholders.
REGULATION | Aug 21, 2026, 08:16 PM UTC
L
Entera appoints Riccardo Paolo Camisasca as Chief Medical Officer
Entera (ENTX) appoints Riccardo Paolo Camisasca, M.D., as Chief Medical Officer ahead of planned EB613 Phase 3 initiation, according to a company release.
REGULATION | Aug 18, 2026, 12:00 PM UTC
M
Entera Bio Presents Phase 2 Data on EB613
Entera Bio presents Phase 2 data on osteoporosis treatment
EQUITY | Aug 04, 2026, 12:31 PM UTC
L
ENTX to Participate in Canaccord Conference
ENTX to present at conference
EQUITY | Jul 31, 2026, 08:30 PM UTC
L
ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
EQUITY | Jul 29, 2026, 07:00 PM UTC
L
ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
EQUITY | Jul 27, 2026, 12:31 PM UTC
H
NXTS Plunges 48%
NXTS leads small cap negative movers premarket, down 48% on momentum, followed by WHLR, KIDZ, and others
EQUITY | Jun 23, 2026, 12:22 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
ENTX Receives FDA Feedback
Entera Bio receives FDA's positive feedback for its Phase 3 registrational protocol for EB613 tablet to treat osteoporosis
EARNINGS | Jun 22, 2026, 05:23 PM UTC
M
Healthcare Stocks Moving
Multiple healthcare stocks are moving in Monday's intraday session, with gainers including Tenon Medical and Aditxt, and losers including Aethlon Medical and Atlantic International
EQUITY | Jun 22, 2026, 05:23 PM UTC
L
ENTX Vol Pops
ENTX volume is popping
EQUITY | Jun 22, 2026, 04:16 PM UTC
H
ENTX Receives FDA Feedback
ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
EQUITY | Jun 22, 2026, 12:31 PM UTC